Literature DB >> 19473336

Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer.

Shelby D Reed1, Kevin A Schulman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19473336     DOI： 10.1111/j.1524-4733.2009.00564.x

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  1 in total

1.  Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence.

Authors:  Peter S Hall; Claire Hulme; Christopher McCabe; Yemi Oluboyede; Jeff Round; David A Cameron
Journal:  Pharmacoeconomics       Date:  2011-05       Impact factor: 4.981
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.